PE20231098A1 - Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune - Google Patents
Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmuneInfo
- Publication number
- PE20231098A1 PE20231098A1 PE2022000967A PE2022000967A PE20231098A1 PE 20231098 A1 PE20231098 A1 PE 20231098A1 PE 2022000967 A PE2022000967 A PE 2022000967A PE 2022000967 A PE2022000967 A PE 2022000967A PE 20231098 A1 PE20231098 A1 PE 20231098A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- substituted
- oxo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000005934 immune activation Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 abstract 2
- 102100022732 Diacylglycerol kinase beta Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- KWMUSDDZNYHIBR-UHFFFAOYSA-N 3-amino-1h-quinolin-2-one Chemical class C1=CC=C2NC(=O)C(N)=CC2=C1 KWMUSDDZNYHIBR-UHFFFAOYSA-N 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- HLEYIPIDTFXISR-UHFFFAOYSA-N CS(=O)(=O)C=1C=CC2=C(N=C(O2)C2(CCN(CC2)C2=C(C(N(C3=CC=CC=C23)C)=O)C#N)C)C=1 Chemical compound CS(=O)(=O)C=1C=CC2=C(N=C(O2)C2(CCN(CC2)C2=C(C(N(C3=CC=CC=C23)C)=O)C#N)C)C=1 HLEYIPIDTFXISR-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Refiere a compuestos de aminoquinolona de la formula general (I), en donde R1 es -C(=O)N(H)C2H5, -C(=O)N(CH3)2, entre otros; R2 se selecciona entre fenilo, naftilo y heteroarilo de 5 a 10 miembros, el cual se sustituye 1-4 veces con hidroxialquilo C1-C6, haloalcoxi C1-C6, entre otros; R3, R4 y R5 se seleccionan de (C1-C2-alcoxi)-(alquilo C1-C6)-, (alcoxi C1-C2)-(alcoxi C1-C6)-, cicloalquiloxi C3-C6, entre otros; R6 y R7 se seleccionan de alquilo C1-C4, alcoxi C1-C4, hidroxi, entre otros; R8 se selecciona de metilo y etilo; R9 y R10 junto al atomo de nitrogeno al que estan unidos representan un grupo heterocicloalquilo de 4 a 7 miembros sustituido con alquilo C1-C4, cicloalquilo C3-C4, hidroxi y oxo; R12 y R15 son H o alquilo C1-C4; R11, R13 y R14 se seleccionan de fenilo y heteroarilo de 5-6 miembros, el cual se sustituye con haloalquilo C1-C2, cicloalquilo C3-C4, -N(R9)(R10), entre otros; R16 se selecciona de alquilo C1-C4, cicloalquilo C3-C4 y haloalquilo C2-C4; R17 representa un grupo heterocicloalquilo de 4 a 7 miembros sustituido 1-3 veces con alquilo C1-C4, cicloalquilo C3-C4, alcoxi C1-C4, hidroxi y oxo; R18 y R19 son H, metilo o etilo, R20 es un grupo (heterocicloalquilo de 4 a 7 miembros)-(alquilo C1-C4) ; y m y n son 1, 2 o 3. Dichos compuestos son 4-{4-[5-(metanosulfonil)-1,3-benzoxazol-2-il]-4-metilpiperidin-1-il}-1-metil-2-oxo-1,2-dihidroquinolina-3-carbonitrilo, entre otros. Ademas, la presente refiere a su metodo de preparacion con compuestos intermedios de formulas (II) y (III) y a una composicion farmaceutica que los compone junto a un inhibidor de DGK? para el tratamiento o profilaxis de cancer, o una afeccion con una respuesta inmune desregulada, o un trastorno asociado con la senalizacion aberrante de DGK?.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19212252 | 2019-11-28 | ||
EP20181065 | 2020-06-19 | ||
PCT/EP2020/083198 WO2021105117A1 (en) | 2019-11-28 | 2020-11-24 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20231098A1 true PE20231098A1 (es) | 2023-07-18 |
Family
ID=73476184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000967A PE20231098A1 (es) | 2019-11-28 | 2020-11-24 | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune |
Country Status (19)
Country | Link |
---|---|
US (1) | US20230148194A1 (es) |
EP (1) | EP4065574A1 (es) |
JP (1) | JP2023504249A (es) |
KR (1) | KR20220122637A (es) |
CN (1) | CN115003665A (es) |
AU (1) | AU2020393384A1 (es) |
BR (1) | BR112022010112A2 (es) |
CA (1) | CA3163105A1 (es) |
CL (1) | CL2022001406A1 (es) |
CO (1) | CO2022007005A2 (es) |
CR (1) | CR20220236A (es) |
DO (1) | DOP2022000110A (es) |
EC (1) | ECSP22041839A (es) |
IL (1) | IL293213A (es) |
JO (1) | JOP20220131A1 (es) |
MX (1) | MX2022006466A (es) |
PE (1) | PE20231098A1 (es) |
TW (1) | TW202134230A (es) |
WO (1) | WO2021105117A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
KR20220131918A (ko) | 2019-12-24 | 2022-09-29 | 카나 바이오사이언스, 인코포레이션 | 다이아실글리세롤 키나제 조절 화합물 |
WO2022271684A1 (en) * | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022298639A1 (en) * | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) * | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
TW202342477A (zh) * | 2022-03-01 | 2023-11-01 | 香港商英矽智能科技知識產權有限公司 | 二醯基甘油激酶(DGK) α抑制劑及其用途 |
WO2024053650A1 (ja) * | 2022-09-06 | 2024-03-14 | 小野薬品工業株式会社 | ジアシルグリセロールキナーゼαおよび/またはζ阻害活性を有する化合物およびその医薬用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4435479A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Chinolon- und Naphthyridoncarbonsäure-Derivate |
DK1117659T3 (da) * | 1998-09-29 | 2004-03-22 | Wyeth Corp | Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser |
AU2003221786A1 (en) | 2002-04-25 | 2003-11-10 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
US7884127B2 (en) * | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
DE10337191A1 (de) * | 2003-08-13 | 2005-03-17 | Bayer Healthcare Ag | Neue Verwendung von Chinolon-Antibiotika |
WO2005087752A2 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
NZ555419A (en) | 2004-11-03 | 2009-07-31 | Curis Inc | Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto |
GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
FR2953834B1 (fr) | 2009-12-10 | 2012-01-13 | Galderma Res & Dev | Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
ES2593256T3 (es) * | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
PT2592933T (pt) | 2010-07-16 | 2017-05-23 | Gaweco Anderson | Inibidores de mif e suas utilizações |
EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
WO2012142498A2 (en) | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
PE20141371A1 (es) * | 2011-08-29 | 2014-10-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
EP3071203B1 (en) | 2013-11-18 | 2020-12-23 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
WO2017014170A1 (ja) * | 2015-07-17 | 2017-01-26 | 武田薬品工業株式会社 | 複素環化合物 |
WO2017019723A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Aza-cyanoquinolinone pde9 inhibitors |
WO2017158619A1 (en) | 2016-03-15 | 2017-09-21 | Natco Pharma Limited | A modified process for the preparation of ceritinib and amorphous form of ceritinib |
SI3814348T1 (sl) | 2018-06-27 | 2023-10-30 | Bristol-Myers Squibb Company | Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic |
EP3814347B1 (en) | 2018-06-27 | 2023-05-03 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as t cell activators |
US20220081409A1 (en) | 2019-01-08 | 2022-03-17 | Nanjing Transthera Biosciences Co., Ltd. | Pde9 inhibitor and use thereof |
CN111471059B (zh) | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
EP3939588A4 (en) | 2019-03-08 | 2023-01-11 | Transthera Sciences (Nanjing), Inc. | USES OF PHOSPHODIESTERASE INHIBITORS |
-
2020
- 2020-11-24 KR KR1020227021418A patent/KR20220122637A/ko unknown
- 2020-11-24 WO PCT/EP2020/083198 patent/WO2021105117A1/en active Application Filing
- 2020-11-24 CA CA3163105A patent/CA3163105A1/en active Pending
- 2020-11-24 AU AU2020393384A patent/AU2020393384A1/en active Pending
- 2020-11-24 MX MX2022006466A patent/MX2022006466A/es unknown
- 2020-11-24 JO JOP/2022/0131A patent/JOP20220131A1/ar unknown
- 2020-11-24 CN CN202080094610.6A patent/CN115003665A/zh active Pending
- 2020-11-24 US US17/780,890 patent/US20230148194A1/en active Pending
- 2020-11-24 PE PE2022000967A patent/PE20231098A1/es unknown
- 2020-11-24 JP JP2022531001A patent/JP2023504249A/ja active Pending
- 2020-11-24 IL IL293213A patent/IL293213A/en unknown
- 2020-11-24 BR BR112022010112A patent/BR112022010112A2/pt unknown
- 2020-11-24 CR CR20220236A patent/CR20220236A/es unknown
- 2020-11-24 EP EP20808438.4A patent/EP4065574A1/en active Pending
- 2020-11-27 TW TW109141886A patent/TW202134230A/zh unknown
-
2022
- 2022-05-25 CO CONC2022/0007005A patent/CO2022007005A2/es unknown
- 2022-05-25 EC ECSENADI202241839A patent/ECSP22041839A/es unknown
- 2022-05-25 DO DO2022000110A patent/DOP2022000110A/es unknown
- 2022-05-27 CL CL2022001406A patent/CL2022001406A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3163105A1 (en) | 2021-06-03 |
CO2022007005A2 (es) | 2022-06-10 |
BR112022010112A2 (pt) | 2022-09-06 |
MX2022006466A (es) | 2022-08-17 |
JOP20220131A1 (ar) | 2023-01-30 |
AU2020393384A1 (en) | 2022-06-09 |
ECSP22041839A (es) | 2022-06-30 |
US20230201186A1 (en) | 2023-06-29 |
CR20220236A (es) | 2022-10-03 |
JP2023504249A (ja) | 2023-02-02 |
CN115003665A (zh) | 2022-09-02 |
WO2021105117A1 (en) | 2021-06-03 |
CL2022001406A1 (es) | 2023-03-10 |
KR20220122637A (ko) | 2022-09-02 |
EP4065574A1 (en) | 2022-10-05 |
IL293213A (en) | 2022-07-01 |
US20230148194A1 (en) | 2023-05-11 |
DOP2022000110A (es) | 2022-06-30 |
TW202134230A (zh) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20231098A1 (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune | |
ES2855732T3 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP | |
AR105104A1 (es) | Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR073450A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
CO5300399A1 (es) | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
CU24448B1 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
AR061974A1 (es) | Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion | |
ES2630079T3 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
BRPI0907122B8 (pt) | compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos | |
AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
AR082004A1 (es) | Compuestos de fusion de piridina | |
AR096613A1 (es) | Moduladores de la acetil-coa carboxilasa | |
AR066154A1 (es) | Derivados de piperidina / piperazina | |
AR074337A1 (es) | Derivados heterociclicos de oxazol y oxadiazol, medicamentos que los contienen,metodo de preparacion y uso de los mismos para tratar y/o prevenir enfermedades hiperproliferativas y angiogenicas,entre otras. | |
AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
AR078632A1 (es) | Compuestos esteroidales modificadores de la melanogenesis y sus usos | |
AR118435A1 (es) | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos | |
ECSP11011164A (es) | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica | |
AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
AR069304A1 (es) | Inhibidores del transportador equilibrativo de nucleosidos ent1 | |
CO5540388A2 (es) | Nuevas arisulfonamidas como agentes antivirales | |
AR052174A1 (es) | Sulfonamido - macrociclos y sus sales como inhibidoras de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso |